Detail page

Knowledge Web

Person

Thomas Wagner

Onkologe

Name	Thomas Wagner
Place	Sonstiges Ausland / Unbekanntes Land
Gender	männlich
Academic degree	Dr. med.
Profession	Onkologe (characteristic profession) Arzt
Variant	Thomas E. Wagner
Further information	Mitbegründer der Perseus PCI; tätig bei Elios Therapeutics LLC in
Source	Homepage:Thomas Wagner, PHD: http://www.eliostherapeutics.com/ (Stand:21.12.2021)
Record type	Person
GND-Identifier	1248139089
Record ID	1248139089
Involved in show all Pals1 prevents Rac1-dependent colorectal cancer cell metastasis by inhibiting Arf6 A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis Pathological predictors of metastatic disease in testicular non-seminomatous germ cell tumors: which tumor-node-metastasis staging system? Long-term neurotoxicity and quality of life in testicular cancer survivors—a nationwide cohort study A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor–dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2 Preclinical testing of a novel personalized cancer vaccine for all solid tumors and all patients Von Menschen, Städten, Dingen, Zeichen und Medien

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Thomas Wagner

Pals1 prevents Rac1-dependent colorectal cancer cell metastasis by inhibiting Arf6

A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis

Pathological predictors of metastatic disease in testicular non-seminomatous germ cell tumors: which tumor-node-metastasis staging system?

Long-term neurotoxicity and quality of life in testicular cancer survivors—a nationwide cohort study

A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor–dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2

Preclinical testing of a novel personalized cancer vaccine for all solid tumors and all patients

Von Menschen, Städten, Dingen, Zeichen und Medien